Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.
https://news.vicc.org/2017/07/drivers-of-breast-cancer-metastasis/
![Drivers of breast cancer metastasis](/sites/default/files/drupalfiles/vanderbilt_news//breastcancer_wellcome736e3-copy-75x75.jpg)